According to him, the policy note recognises that these issues would require some regulatory interventions from concerned ministries.
There have been persisting concerns about alleged unfair business ways in the pharmaceuticals and healthcare space while in certain matters the fair trade regulator has passed orders against entities indulging in such practices.
"In deciding these cases, it was observed that a number of issues go beyond competition law," Mital said.
Among other issues, the policy note said that unreasonably high trade margins contributes towards high drug prices and electronic trading of drugs could be an option to spur competitive pricing ways.
The watchdog's policy note had said that one major factor that contributes to high drug prices in India is the unreasonably high trade margins.
"The high margins are a form of incentive and an indirect marketing tool employed by drug companies," an official release had said quoting the policy note.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)